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Langerhans cells (LCs) populate the mucosal epithe-
lium, a major entry portal for pathogens, yet their
ontogeny remains unclear. We found that, in contrast
to skin LCs originating from self-renewing radiore-
sistant embryonic precursors, oral mucosal LCs
derive from circulating radiosensitive precursors.
Mucosal LCs can be segregated into CD103+CD11blo
(CD103+) and CD11b+CD103 (CD11b+) subsets. We
further demonstrated that similar to non-lymphoid
dendritic cells (DCs), CD103+ LCs originate from
pre-DCs, whereas CD11b+ LCs differentiate from
both pre-DCs and monocytic precursors. Despite
this ontogenetic discrepancy between skin and
mucosal LCs, the transcriptomic signature and
immunological function of oral LCs highly resemble
those of skin LCs but not DCs. These findings, along
with the epithelial position, morphology, and expres-
sion of the LC-associated phenotype strongly sug-
gest that oral mucosal LCs are genuine LCs. Collec-
tively, in a tissue-dependent manner, murine LCs
differentiate from at least three distinct precursors
(embryonic, pre-DC, and monocytic) in steady state.
INTRODUCTION
Langerhans cells (LCs) are antigen-presenting dendritic cells
(DCs) that have critical roles in regulating immunity and tolerance.
LCs are characterized by several parameters: (1) they reside in
stratified epithelia, including the skin epidermis and mucosal
epithelium; (2) LCs express the C-type lectin receptor langerin
(CD207), enabling them to form (3) the unique rod- or tennis-
racket-shaped endocytic vesicles termed Birbeck granules, the
hallmark of LCs (Romani et al., 2010); and (4) LCs also express
high amounts of epithelial cell adhesion molecule (EpCAM;
CD236), a cell-surface protein characteristic of some epithelia
and found toenable LCmotility andmigration (Gaiser et al., 2012).In the past decade, there has been a major advance in the
characterization of epidermal LCs. It has been shown that LC
precursors first seed the epidermis on embryonic day 18 and
proliferate in situ after birth to form a dense self-renewing and ra-
dioresistant population (Chorro et al., 2009; Merad et al., 2002).
LCs are the only cells expressing major histocompatibility com-
plex class II (MHCII) in the epidermis in a steady state, and they
are well equipped to sample antigen and migrate to local lymph
nodes (LNs) during steady state and inflammatory conditions
(Hemmi et al., 2000; Kripke, 1990). In addition to having an
embryonic origin, epidermal LCs can differentiate from Gr1hi
monocytes under inflammatory conditions, indicating the exis-
tence of an additional source for these cells in vivo (Ginhoux
et al., 2006; Nagao et al., 2012; Sere´ et al., 2013). This finding
has been corroborated by a recent study demonstrating that
lysozyme M (lysM)-expressing myeloid cells constituted about
10% of epidermal LCs in a steady state (Nagao et al., 2012).
Given that most infections begin with pathogens entering the
host through mucosal surfaces rather than the skin, mucosal
LCs are of major importance for human health. Yet, although
epidermal LCs have been extensively studied, the origin and
development of mucosal LCs remain elusive. LCs are found in
various type II mucosal tissues (mucosal surfaces covered by
stratified epithelia), such as the oral mucosa, the lower female
reproductive tract, and the cornea. The oral mucosa represents
an attractive site in this regard, given that it comprises various
mucosal niches, each of which contains distinct frequencies of
LC and DC subsets (Hovav, 2014). Similar to their equivalents
in the epidermis, oral LCs residing in the epithelium express lan-
gerin and EpCAM and contain Birbeck granules (Arizon et al.,
2012; Kotani et al., 1991; Newcomb and Powell, 1986). Further-
more, several studies have demonstrated a high similarity be-
tween the structure and function of the buccal and skin immune
systems (Barrett et al., 1993; Etchart et al., 2001; Le Borgne
et al., 2006). In addition to the buccal mucosa, the keratinized
gingival mucosa represents another important tissue for the
study of LCs. The gingiva is constantly exposed to the bacterial
plaque attached to the tooth surface, which in many cases in-
duces destructive immunity and causes the highly prevalent
periodontitis and the associated adverse systemic conditions.
LCs are ideally positioned in the gingiva to monitor the adjacentImmunity 43, 369–381, August 18, 2015 ª2015 Elsevier Inc. 369
biofilm, and we have recently provided direct evidence of the
protective role of LCs in periodontitis (Arizon et al., 2012). Oral
LCs are also proposed to be involved in a large number of oral
pathologies (Hovav, 2014). Collectively, these findings highlight
the critical role of oral LCs in orchestrating mucosal immunity,
thus emphasizing the importance of studying their biology.
Emerging evidence suggests that in addition to ontogeny, the
final differentiation of DCs and macrophages is shaped by their
tissues of residence (Gosselin et al., 2014; Lavin et al., 2014;
Schlitzer et al., 2012). Here, we show that under steady-state
conditions, oral mucosal LCs develop from the common DC pre-
cursor (CDP) and pre-DC differentiation pathway, as well as from
monocytes. We have found that the phenotypes, function, and
transcriptomic signatures of mucosal LCs are similar to those
of classical skin LCs. This study thus demonstrates that in a
tissue-dependent manner, LCs arise from both embryonic and
bone marrow precursors at steady state.
RESULTS
LCs Gradually Populate the Oral Epithelium after Birth
We first sought to identify LCs of the gingival and buccal mu-
cosa by using strategies that are regularly employed to classify
epidermal LCs. After gating on live CD45+MHCII+CD11c+ cells
(DCs) by flow cytometry (demonstrated in Figure S1A), LCs
were easily identified in the skin and oral tissues on the basis
of the co-expression of langerin and EpCAM (Figure 1A). Lan-
gerin and EpCAM expression, however, was slightly lower in
oral LCs than in epidermal LCs. In addition, the percentages
of LCs were considerably lower in oral tissues than in skin,
such that they represented 5%–15% and 15%–25% of total
DCs in the gingival and buccal tissues, respectively. Next, we
verified the epithelial localization of oral LCs by separating
the epithelium from the lamina propria prior to flow cytometry
analysis. As expected, oral LCs were mostly located in the
epithelium (Figure 1B). Of note, we found low frequencies of
langerinEpCAMMHCII+ cells in the epithelial fraction of the
buccal (10%) and gingival (20%) mucosa. Further analysis
of this population indicated that most cells expressed macro-
phage-associated markers (CD11b+F4/80+CD64hiCD24) and
resembled macrophages, whereas the rest might have repre-
sented differentiating LCs given that they expressed the
CD64CD24+ phenotype (Figure S1C). To further demonstrate
the epithelial localization of LCs, we performed whole-mount
immunofluorescence staining. As demonstrated in Figure 1C,
in the buccal epithelium, LCs were uniformly co-stained with
langerin and MHCII antibodies and generated a typical network
similar to that of epidermal LCs. In the gingiva, however, in
addition to identifying LCs, we observed a smaller population
(20%) of langerinMHCII+ cells (Figures 1C and S1D), pre-
sumed to be macrophages as demonstrated above by flow
cytometry and macroscopic analysis. We then assessed the
development of LCs in the oral mucosa after birth. Buccal
LCs first appeared in the tissue 1 week after birth, and their fre-
quencies gradually increased during the subsequent 7 weeks
(Figure 1D). Analysis of the gingiva was more challenging, given
that the gingiva is not completely developed until the teeth
erupt, a process occurring in mice between the second and
third weeks of life (Lungova´ et al., 2011). We thus analyzed370 Immunity 43, 369–381, August 18, 2015 ª2015 Elsevier Inc.the maxilla containing the pre-gingiva (weeks 0–3) and gingiva
(beyond week 4), a strategy that increased the overall DC pop-
ulation and proportionally decreased the percentages of LCs.
We found that LCs appeared in the gingiva between the first
and second weeks of life, and their numbers increased gradu-
ally until they achieved a mature phenotype approximately 7–
8 weeks after birth (Figure 1D). Immunofluorescence analysis
on gingival cross sections supported these findings, given
that langerin-expressing cells were readily detected in the
gingival epithelium 3 weeks after birth (Figure 1E). Histology
and immunofluorescence staining demarcating the gingival
epithelium and lamina propria are provided in Figure S1E.
Taken together, skin and oral LCs share epithelial localization
and expression of langerin and EpCAM. Whereas oral LCs
populate the mucosa after birth with delayed kinetics, in
epidermal LCs, local precursors undergo a burst of proliferation
during the first week of life (Figure S1F).
Oral LCs Originate from Circulating Precursors
The gradual arrival of LCs to the oral mucosa suggests that
mucosal LCs might not rapidly differentiate from local precur-
sors, as has been shown for epidermal LCs (Merad et al.,
2002). To address this issue, we adoptively transferred lethally
irradiated CD45.2+ B6 mice with bone marrow (BM) purified
from congenic CD45.1+ mice. As expected, after reconstitu-
tion, the radioresistant (CD11c+langerin+EpCAM+) LCs in the
epidermis were of host origin (Figure 2A). In contrast, LCs of
the gingival and buccal mucosa originated from the donor.
The repopulation kinetics of LCs in the oral mucosa were rela-
tively rapid but were slower than those observed in the spleen
(Figures S2A and S2B). Donor-derived LCs were visible in the
mucosa a few days after BM transplantation and composed
50% of the total LC population 12–13 days after transplanta-
tion (Figure 2A). To directly examine the origin of oral LCs,
we generated parabiotic mice by pairing CD45.2+ B6 mice
with congenic CD45.1+ mice so that they shared the same
blood circulation but had separate organs. 14 days after pair-
ing, B cells of the two parabionts were equally distributed in
the circulation (Figure S2C). LCs were analyzed 2 months
after parabiosis, and as expected, whereas epidermal LCs re-
mained of host origin, donor-derived LCs were found in
the gingival and buccal mucosa of each parabiont (20%–
25%) (Figure 2B). Collectively, these results demonstrate
that in contrast to epidermal LCs, oral mucosal LCs are radio-
sensitive and originate from circulating precursors at steady
state.
Differential Repopulation Kinetics of LCs in the Skin and
Oral Mucosa
To further characterize the repopulation of LCs in the oral mu-
cosa, we utilized the langerin-DTR transgenic mice that allow
conditional ablation of langerin-expressing cells by administra-
tion of diphtheria toxin (DT) (Bennett et al., 2005). 24–48 hr after
DT treatment, LCs were depleted from the skin and oral tissues
(Figure S2D). Unlike epidermal LCs, which failed to restore their
numbers during the following 3 weeks, oral LCs began to repo-
pulate the gingival and buccal tissues immediately after deple-
tion (Figures 2C and S2D). In addition, oral LCs completely
restored their original numbers in the tissue within 2 weeks. We
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Figure 1. Characterization of Oral Mucosal LCs and Their Populating Kinetics after Birth
(A) Skin and oral (gingival and buccal) mucosal tissues were processed from B6 mice for the extraction of single-cell cultures. After gating on live CD45+
MHCII+CD11c+ cells, LCs were identified according to the expression of langerin and EpCAM.
(B) Epithelial and dermal or lamina propria layers were prepared from the skin and oral tissues, and LCs were identified as described above. Data are repre-
sentative of at least six independent experiments.
(C) Epithelial layers from naive B6 mice were stained for MHCII (green), langerin (red), and DAPI (blue) and analyzed by confocal microscopy. Images are
representative of at least three independent experiments.
(D) Buccal and gingival tissues were collected form B6 mice 7, 14, 21, and 56 days after birth, and the frequencies of LCs were monitored by flow cytometry as
described above. Data are representative of three independent experiments.
(E) Gingival tissues were harvested at various days after birth and stained with langerin (red) and DAPI (blue) for immunofluorescence analysis. Scale bars
represent 50 mm.
See also Figure S1.next evaluated the labeling kinetics of oral LCs after continuous
administration of BrdU. In agreement with their rapid turnover
rate, oral LCs labeled with BrdU had much faster kinetics than
did epidermal LCs (Figure 2D). Whereas 50% of oral LCs were
labeled within 5–6 days, fewer than 10% of epidermal LCs
were labeled at this time point. These findings thus indicate
that LCs repopulate the skin and oral tissuewith different kinetics
at steady state.
Oral Mucosal LCs Have Diverse Phenotypes
Our data suggest that oral mucosal and epidermal LCs originate
from different precursors. We thus asked whether these cells
also have differential phenotypes and performed an extensivephenotypic analysis. In agreement with our earlier observation,
langerin, EpCAM, and CD11c expression was slightly lower in
oral LCs than in epidermal LCs (Figure 3A). It is also appeared
that a fraction of the oral LC population had a higher activation
state than did epidermal LCs, given that they slightly elevated
the expression of MHCII and the co-stimulatory CD86 molecule.
However, neither mucosal nor epidermal LCs uniformly ex-
pressed Ly6C or Ly6G. We next revealed considerable differ-
ences between mucosal and epidermal LCs in the expression
of CD103 and CD11b. CD103 was highly expressed by a large
fraction of oral mucosal LCs, whereas epidermal LCs did not ex-
press CD103. In sharp contrast, whereas epidermal LCs highly
expressed the integrin CD11b, in oral LCs, only part of theImmunity 43, 369–381, August 18, 2015 ª2015 Elsevier Inc. 371
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Figure 2. Origin and Repopulation Kinetics of
Oral Mucosal LCs
(A) Kinetics of LC reconstitution in lethally irradiated
CD45.2+ B6mice transplanted with BM purified from
CD45.1+ B6 mice. Data are representative of two
independent experiments.
(B) CD45.1+ B6 and CD45.2+ B6mice were joined for
the generation of parabiotic pairs, and homeostasis
of LCs was analyzed 8 weeks after parabiosis
was induced in each parabiont. Representative
flow cytometry plots and the average of chimerism
(bar graph) from two independent experiments are
shown as mean ± SEM (n = 5 pairs).
(C) Langerin-DTRmice were treated with DT, and the
kinetics of LC repopulation in the skin, gingival, and
buccal mucosa were analyzed by flow cytometry.
Representative data of one out of three independent
experiments are shown as mean ± SEM (n = 3).
(D) BrdU-labeling kinetics of LCs during continuous
exposure to BrdU. Representative data of one out of
two independent experiments are shown as mean ±
SEM (n = 3).
See also Figure S2.population expressed CD11b. A similar pattern of segregated
expression in oral LCs was also observed for F4/80 and CD205
(Figure 3A).
The heterogeneity observed in the expression patterns of
certain cell-surface molecules, particularly CD103 and CD11b,
led us to the assumption that oral mucosal LCs resemble con-
ventional DCs residing in most non-lymphoid tissues. We there-
fore segregated oral LCs on the basis of CD103 and CD11b
expression as previously demonstrated (Ginhoux et al., 2009).
As depicted in Figure 3B, two populations of CD103CD11b+
and CD103+CD11blo LCs, hereafter referred to as CD11b+
LCs and CD103+ LCs, respectively, were clearly identified in
gingival and buccal mucosa. Of note, the low CD11b expression
on CD103+ cells was unique to LCs, given that similar to DCs in
the dermis and lungs, CD103+ DCs in the lamina propria were
mostly CD11b (Figure S2E; Ginhoux et al., 2009). Further anal-
ysis revealed that CD103+ LCs and CD11b+ LCs possessed
distinct phenotypes. Whereas langerin and EpCAMwere equally
expressed on both subsets, a large fraction of CD11b+ LCs,
but not CD103+ LCs, expressed both the chemokine receptor
CX3CR1 and CD172 (Figure 3C). Additionally, expression of
F4/80 by these subsets varied between the buccal and gingival
tissues, such that CD11b+ LCs expressed F4/80 in both tissues,
whereas gingival but not buccal CD103+ LCs expressed it372 Immunity 43, 369–381, August 18, 2015 ª2015 Elsevier Inc.partially. We next analyzed expression of
the C-type lectin receptor CLEC9A and
chemokine receptor XCR1, which are
known to be expressed specifically on
CD103+langerin+ DCs, such as those in
the lungs (Figure S2F; Malissen et al.,
2014). We found that CD103+ LCs lacked
expression of CLEC9A, and only a small
fraction (10%–20%) of this subset stained
positively for XCR1 (Figure 3C). Collec-
tively, these data suggest that although
oral mucosal and epidermal LCs sharesimilar LC-specific characteristics, they differ in their ability to
express various cell-surface markers. Moreover, oral mucosal
LCs can be segregated into two phenotypically distinct subsets
on the basis of CD103 and CD11b expression, which suggests
they are derived from different precursors.
CDPs and Pre-DCs Give Rise to Oral Mucosal CD103+
LCs and CD11b+ LCs
Conventional DCs in non-lymphoid tissues differentiate from
pre-DCs, whereas the transcription factors Flt3, IRF8, and Id2
play a role in the differentiation of CD103+ DCs and part of the
CD11b+ DC subset (Ginhoux et al., 2009; Hacker et al., 2003).
Because conventional DCs and oral mucosal LCs are highly
similar with regard to their inclusion of CD103 and CD11b
expression, we envisaged that the CDP and pre-DC develop-
mental axis might also give rise to mucosal LCs. First, we
analyzed oral LCs in Flt3-deficient mice and found a large reduc-
tion (50%) in the frequencies of total LCs in the tissues (Fig-
ure S3A). The percentages of epidermal LCs were not affected
in these mice. We also observed that the CD103+ LC population
was almost completely abolished in Flt3-deficient mice, and the
CD11b+ LC subset was only partially diminished (Figures 4A and
4B). IRF8-deficent mice presented with a phenotype similar to
that of Flt3-deficient mice. We next analyzed Id2-deficient
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Figure 3. Phenotypic Characterization of Oral Mucosal LCs
(A) Representative histograms demonstrating the expression of various phenotypic markers on LCs in the skin and oral mucosa.
(B and C) LCs were segregated on the basis of their ability to express CD103 and CD11b (B), and the expression intensity of langerin, EpCAM, F4/80, CX3CR1,
CD172, XCR1, and CLEC9A on each LC subset is presented (C). An average of 600–1,000 cells were analyzed for each cell subset. Data are representative of
three independent experiments.mice and found that skin LCs were absent, as recently reported
(Sere´ et al., 2013). A large reduction in oral LCs was also found
(Figure S3A) mostly in CD103+ LCs but also in buccal, but not
gingival, CD11b+ LCs (Figures 4A and 4B). Additionally, mucosal
LCs that were left in Id2-deficient mice exhibited reduced
expression of langerin (Figure S3B), as recently shown in short-
term LCs infiltrating the epidermis of Id2-deficient mice during
inflammation (Sere´ et al., 2013).
To directly examine that oral LCs differentiate from CDP and
pre-DCs, we first purified CDPs for reconstitution assays.
CDPs were sorted by flow cytometry from BM of CD45.2+
Cx3cr1GFP/+ mice after gating on Lin, Sca1, Flt3+, c-Kitint,
CX3CR1+, and CD115+ cells (Figure S3C). The purified
CD45.2+ CDPs (23 104 cells), together with 23 106 CD45.1+ to-
tal BM cells from B6 mice to prevent mouse death, were adop-
tively transferred into lethally irradiated CD45.1+ B6 mice.
4 weeks after transplantation, the skin and oral tissues werecollected for analysis. As expected, epidermal LCs were not
affected in this experimental system. However, we identified
LCs (in addition to CD11c+ cells) in the gingival and buccal mu-
cosa that were CD45.2+, demonstrating that they originated
from CDPs (Figure S3D). We also found that CDPs contributed
mainly (60%–70%) to CD103+ LCs and to a lesser extent
(30%–40%) to CD11b+ LCs. (Figure S3D). We next sorted by
flow cytometry pre-DCs (LinCD11cintFlt3+Sirpaint) from
CD45.1+ mice (Figure S3E) and transferred them (5 3 104 cells),
together with 2 3 106 CD45.2+ total BM cells from B6 mice, into
lethally irradiated CD45.2+ B6 mice. Similar to CDPs, besides
differentiating into CD11c+ cells, pre-DCs gave rise also to
oral mucosal LCs, mostly to CD103+ LCs (80%) and much
less to CD11b+ LCs (20%) (Figure 4B). We then tried
to examine whether the transferred pre-DCs also contributed
to LCs in other mucosal tissues, such as the vagina and
cornea. Unfortunately, even though we were able to detectImmunity 43, 369–381, August 18, 2015 ª2015 Elsevier Inc. 373
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Figure 4. Mucosal CD103+ LCs and Part of CD11b+ LCs Depend on Flt3, IRF8, and Id2 for Their Development
(A and B) Representative flow cytometry plots (A) and graphs (B) demonstrate the frequencies of CD103+ LCs and CD11b+ LCs in B6 WT, Flt3/, Irf8/, and
Id2/ mice. Data were pooled from three (Flt3/; n = 7), four (Id2/; n = 5), or two (Irf8/; n = 4) independent experiments and represent the mean ± SEM.
(C and D) Pre-DCs were purified from CD45.1+ BM cells on the basis of live LinCD11cintFlt3+Sirpaint cells, and the cells (5 3 104 cells) were then transplanted
together with all CD45.2+ BM cells (2 3 106 cells) into lethally irradiated CD45.2+ hosts. Representative fluorescence-activated cell sorting (FACS) plots (C) and
graphs (D) demonstrate the percentages of pre-DC (red)- and CD45.2+ BM (black)-derived CD11c+ cells that further differentiated into LCs and their CD103+ and
CD11b+ subsets. Data were pooled from three independent experiments and represent the mean ± SEM (n = 5).
See also Figure S3.pre-DC-derived CD11c+ cells in these tissues (Figure S3F),
because of the low frequencies of vaginal and corneal LCs, we
were not able to clearly identify pre-DC-derived LCs. Neverthe-
less, we found that vaginal LCs could be segregated into374 Immunity 43, 369–381, August 18, 2015 ª2015 Elsevier Inc.CD103+ LCs and CD11b+ LCs (Figure S3G) and could thus
resemble oral LCs. Taken together, these findings thus suggest
that similar to conventional DCs, oral mucosal LCs can arise from
the CDP and pre-DC differentiation pathway.
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Figure 5. Mucosal LCs Also Differentiate
from Monocytic Origin
(A) Frequencies of LysM+ LCs in skin and oral tis-
sues isolated from Lyz2-cre 3 Rosa26-lsl-YFP
mice. Data are representative of at least three in-
dependent experiments (n = 7–10).
(B) Expression of CD64 on skin LCs, CD11b+ LCs,
and CD103+ LCs of the oral mucosa. Data are
representative of at least three independent ex-
periments (n = 6). An average of 600–1,000 cells
were analyzed for each cell subset.
(C and D) GR-1hi and Gr-1lo monocytes were
labeled in vivo with FITC-conjugated micro-
spheres (Figures S4C–S4E), and 10 days later the
differentiation of oral LCs from FITC-labeled
monocytes was examined by flow cytometry.
Representative flow cytometry plots (C) and
graphs (D) demonstrate the percentages and ab-
solute cell numbers of monocyte-derived LCs.
Data were pooled from three independent experi-
ments and represent the mean ± SEM (n = 9).
(E and F) CD45.1+ monocytes (3 3 105 cells)
were administered intravenously into CD45.2+
Ccr2/Ccr6GFP/GFP mice and were analyzed
10 days later. Representative flow cytometry plots
(E) and graphs (F) depict the frequencies of
monocyte (red)- and host (black)-derived CD11c+
cells that further differentiated into LCs. Data were
pooled from three independent experiments and
represent the mean ± SEM (n = 6).
See also Figures S4 and S5.Oral Mucosal LCs Can Also Differentiate from
Monocytes
The analysis of Flt3-, IRF8-, and Id2-deficient mice suggested
that CD11b+ LCs do not solely develop from CDPs and pre-DC
precursors, given that unlike CD103+ LCs, they were not
completely depleted. In addition, CD11b+ LCs displayed variable
expression of CX3CR1, CD172, and F4/80, suggesting the exis-
tence of multiple precursors. Because monocytes were found
to give rise to DCs in certain tissues, and Gr1+ cells can differen-
tiate into epidermal short-termLCs (Ginhouxet al., 2009;Ginhoux
et al., 2006; Sere´ et al., 2013), we next examined whether mono-
cytes also contribute to the population of oral LCs. Using Lyz2-
cre 3 Rosa26-lsl-YFP mice for lineage tracing, we found that
about 20%–24%of oral LCs originated from LysM+ cells (Figures
5A andS4A). Similar frequencies of LysM+ LCswere also found in
the cornea and vaginal mucosa (Figures S4A and S4B). In agree-
ment with a previous study, approximately 10%–30% of
epidermal LCs were of LysM origin (Nagao et al., 2012). WeImmunity 43, 369–381next stained LCs with an antibody against
CD64, a molecule that allows distinguish-
ing between monocyte-derived DCs and
conventional DCs (Langlet et al., 2012).
Our analysis showed that CD103+ LCs
and skin LCs did not express CD64,
whereas about 12%–20% of CD11b+
LCs stained positive (Figure 5B). To
further examine the contribution of mono-
cytes to oral LCs, we labeled monocytes
in vivo by intravenous injection of FITCmi-crospheres. We selectively labeled Gr-1hi and Gr-1lo monocytes
by administrating alendronate liposomes and PBS liposomes,
respectively, before labeling. Alendronate, like the widely used
clodronate, is capable of depleting monocytes in vivo (Cohen-
Sela et al., 2006). Figures S4C–S4E demonstrate the selective la-
beling of Gr-1hi and Gr-1lo monocytes 24 hr after treatment as
previously reported (Ginhoux et al., 2006). 10 days after labeling,
we were able to detect FITC-labeled LCs in the oral mucosa, and
the contribution of Gr-1hi and Gr-1lo monocytes to mucosal
LCs appeared to be similar (Figures 5C and 5D). To further verify
the monocytic origin of mucosal LCs, we purified CD45.1+
monocytes (Figure S4F) and administered them intravenously
(3 3 105 cells) into CD45.2+ mice lacking both CCR2 and CCR6
(Ccr2/Ccr6GFP/GFP mice). We selected Ccr2/Ccr6GFP/GFP
mice because they had reduced numbers of oral LCs (Figure 6A),
and we thus anticipated an increased possibility of finding
monocyte-derived LCs. Although the total frequencies of
CD45.1-expressing cells were very low, we were able to detect, August 18, 2015 ª2015 Elsevier Inc. 375
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Figure 6. Dependence of Oral Mucosal LCs
on Chemokine Receptors
(A) Gingival and buccal mucosal tissues were
harvested from B6, Cx3cr1GFP/GFP, Ccr2/,
Ccr6GFP/GFP, and Ccr2/Ccr6GFP/GFP mice, and
the reduction in the number of LCs was calculated
in comparison to the number of LCs in B6 mice.
Data were pooled from three independent experi-
ments and represent the mean ± SEM (n = 8 for
single-gene-deficient mice, and n = 3 for double-
gene-deficient mice).
(B andC) Lethally irradiated CD45.1+ B6micewere
reconstituted with a mixture of equal numbers of
wild-type CD45.1+ BM cells and CD45.2+ BM cells
deficient in CCR2 or CCR6. (B) 8 weeks later, the
ratio of CD45.2+ cells to CD45.1+ cells among oral
LCs was calculated by flow cytometry. (C) The
ratios of CD45.2+ cells to CD45.1+ cells among
blood CD11b+MHCII+ cells, blood CD11c+MHCII
cells, gingiva LCs, and buccal LCs were compared
for assessing the role of CCR2 and CCR6 in LC
recruitment. Data were pooled from two indepen-
dent experiments and represent the mean ± SEM
(n = 4 for mucosal tissues, and n = 12 for blood).monocyte-derived CD45.1+ LCs, and also CD11c+ cells, in the
oral mucosa (mainly in the gingiva) but not in the epidermis (Fig-
ure 5E). Furthermore, monocytes contributed solely to CD11b+
but not CD103+ epithelial CD11c+ cells, supporting the mono-
cytic origin of CD11b+ LCs (Figure S5C). We next examined the
differentiation of monocytes to LCs in wild-type chimeric mice
to exclude any differentiation bias due to the lack of CCR2 and
CCR6. Purified CD45.2+ monocytes (5 3 105 cells) were trans-
ferred together with CD45.1+ total BM cells (2 3 104 cells) into
lethally irradiated CD45.1+ mice. 2 weeks later, we were able to
identify CD45.2+ LCs (as well as DCs) in the oral mucosa but
not in the skin (Figure S5A). As indicated above, the transferred
monocytes did not give rise to any CD103+ DCs or LCs (Fig-
ure S5B), ruling out any impact of CCR2 or CCR6 on differentia-
tion into CD11b or CD103 subsets. Collectively, these data
strongly suggest that whereas CD103+ LCs and CD11b+ LCs
arise from CDPs and pre-DCs, a fraction of CD11b+ LCs might
originate from monocytes in the steady state.
CCR2 and CCR6 Are Required for the Recruitment of
LCs to the Oral Mucosa
We next examined which chemokine receptors mediate the
recruitment of LC precursors to the oral mucosa. Because
CCR2 and CCR6 were shown recently to mediate the recruit-
ment of circulating LC precursors to the epidermis under inflam-
matory conditions (Ginhoux et al., 2006; Nagao et al., 2012),
we sought to examine their role in the oral mucosa at steady
state. We also assessed the role of CX3CR1 because it was
shown to mediate the seeding of LC precursors to the epidermis
during embryonic development (Chorro et al., 2009). To this
aim, we quantified the numbers of gingival and buccal LCs in376 Immunity 43, 369–381, August 18, 2015 ª2015 Elsevier Inc.Cx3cr1GFP/GFP, Ccr2/, and Ccr6GFP/GFP
mice. We found that the lack of CCR2 or
CCR6, but not CX3CR1, resulted in a
considerable 50%–60% reduction in thegingival and buccal LCs (Figure 6A). We next analyzed
Ccr2/Ccr6GFP/GFP mice to verify whether both chemokine re-
ceptors mediate the recruitment of two different LC precursors
or a single one. Similar to the results obtained for Ccr2/ or
Ccr6GFP/GFP mice, a reduction of 60% in oral LC numbers
was found in Ccr2/Ccr6GFP/GFP mice, indicating that CCR2
and CCR6 in concert mediate the recruitment of the same oral
LC precursors (Figure 6A).We then testedwhether these chemo-
kine receptors mediate the egression of LC precursors from the
BM to the circulation or whether they are required for entry into
the mucosa. To address this issue, we reconstituted lethally irra-
diated CD45.1+ B6micewith amixture of an equal number of BM
cells from CD45.2+ mice deficient in CCR2 or CCR6 and of BM
cells from wild-type CD45.1+ mice. To validate our chimeras,
we monitored circulating B cells in which their entry to the circu-
lation was independent of the noted chemokine receptors and
found equivalent contributions to B cells from both donors (Fig-
ure S5D). We then compared the ratio of CD45.2+ cells to
CD45.1+ cells in blood andmucosa 4weeks after transplantation
to determine which chemokine receptors were required for entry
of LC precursors into the oral mucosa. As for mucosal LCs,
higher frequencies were found to originate fromwild-type donors
than from chemokine receptor-deficient donors, further support-
ing their role in recruitment of mucosal LC precursors (Figure 6B).
In the blood, MHCII+CD11b+ cells (resembling monocyte-
derived LCs) utilized CCR2 and CCR6 to enter the circulation,
whereas MHCIICD11c+ cells (resembling blood pre-DCs)
required CCR2 alone (Figure 6C). Within the mucosa, CCR2 or
CCR6 was required for mucosal entry of LC precursors origi-
nating from monocytic precursors or pre-DCs, respectively.
Taken together, these results suggest that CCR2 and CCR6
are important for the recruitment of a large fraction of LC precur-
sors to the oral mucosa, whereas their contribution to entry into
the circulation or mucosa varies among LC subsets.
Oral LCs and Skin LCs Have Similar Transcriptomic
Signatures and Functions
The epithelial location of oral mucosal LCs and their ability to
express langerin and EpCAM imply similarity to the classical
epidermal LCs. However, because mucosal LCs are ontogeneti-
cally distinct fromepidermal LCs, it is unclear whether these cells
represent functionally similar LCs. To approach this question in
an unbiasedmanner, we first profiled the global gene expression
of mucosal CD103+ LCs, CD11b+ LCs, skin LCs, lung CD103+
DCs, and lung macrophages. Cells were purified as described
in Figure S6A (two to four replicates per type), and global gene-
expression patterns were analyzed by RNA sequencing. Impor-
tantly, lung CD103+ DCs were included in our analysis because,
akin toCD103+LCs, theydifferentiate frompre-DCs, express lan-
gerin and EpCAM, and are located in mucosal epithelial tissue
(Figure S2F). Additionally, because of the low frequency ofmono-
cyte-derived oral LCs, we were not able to collect sufficient cells
for RNA sequencing; nevertheless, to avoid contamination by
these cells in the purified CD11b+ LC subset, we excluded
them by CD64 staining (Figure S6A). K-mean clustering of
6,208 genes, with expression values at the top 75%, demon-
strated a large set of common gene-expression patterns for
mucosal CD103+ and CD11b+ LCs (Figures 7A and 7B).
CD11b+ andCD103+mucosal LCswere distinct in only 68 genes,
indicating high similarity between these cell subtypes. Hierarchi-
cal clustering of the five cell subtypes, as well as principle-
component analysis, indicated a high resemblance of the two
mucosal LC subtypes (Figures 7A and 7C). Moreover, both
mucosal LC subtypes clearly clustered closer to skin LCs than
to lung CD103+ DCs or lung macrophages. Furthermore, genes
considered critical regulators of epidermal LC differentiation
and survival, such asCsf1r (colony stimulating factor 1 receptor),
were specifically expressed in mucosal and skin LCs (Figure 7B).
It should be noted that despite the clear similarity between
mucosal LCsand skin LCs, somegeneswere uniquely expressed
in mucosal but not in skin LCs or vice versa; for example, Krtdap
(keratinocyte-differentiation-associated protein) was expressed
primarily in mucosal LCs, whereas Mmp9 (matrix metallopepti-
dase 9) was uniquely expressed in skin LCs (Figure 7B).
Next, we studied the function of mucosal LCs in two immuno-
logical settings previously used for examining epidermal LC
function. First, we performed a contact hypersensitivity (CHS)
assay by using low-dose TNCB and found that similar to the
absence of skin LCs, the absence of buccal LCs resulted in
a reduced CHS response (Figure 7D). We next tested the capac-
ity of the various antigen-presenting cells in the buccal mucosa
to present antigen to CD8+ T cells after immunization with
plasmid DNA. We found that buccal DCs, but not LCs, were
able to present antigen and stimulate CD8+ T cells (Figure 7E).
These results are comparable to those obtained after intradermal
plasmid DNA immunization, which we recently published (Elne-
kave et al., 2010). Collectively, these data indicate that besides
having anatomic and phenotypic similarities, mucosal and skin
LCs also have similar transcriptomic signatures and functions,
strongly suggesting that mucosal LCs are bona fide LCs.DISCUSSION
In this study, we have demonstrated that oral mucosal LCs
originate from pre-DCs that differentiate to CD103+ LCs and
CD11b+ LCs and from monocytes that differentiate to only
CD11b+ LCs. Whereas the developmental pathway of oral LCs
is similar to that of conventional DCs, their transcriptomic signa-
tures, functions, and epithelial locations strikingly resemble
those of skin LCs. Such characteristics raise the question of
whethermucosal LCs are simply DCs located in epithelial tissues
or whether they are genuine LCs. This highlights an ongoing
debate regarding the contribution of nature versus nurture (i.e.,
origin versus environment) in cell development and classifica-
tion. Much evidence supports environmental influence on leuko-
cytes differentiation (Lavin et al., 2014; Okabe and Medzhitov,
2014; Rosas et al., 2014). A recent study further showed that
upon transfer to the lungs, microglial cells alter their chromatin
landscaping and gene expression and thus acquire features of
lung alveolar macrophages (Lavin et al., 2014). This indicates
that tissue has a tremendous impact on cell development,
even on differentiated cells. LCs are exclusively located in strat-
ified epithelial tissues, and thus the epithelium is probably
involved in shaping their final differentiation. Indeed, the epi-
dermis has been proposed to instruct the development of em-
bryonic fetal liver macrophages into LCs and to maintain these
cells by expressing bone morphogenetic protein 7 (BMP-7)
and transforming growth factor b (TGF-b) (Hacker et al., 2003;
Yasmin et al., 2013). Under different environmental settings,
these embryonic macrophages develop into a variety of other
cells, such as microglia and alveolar macrophages, further
demonstrating the impact of the tissue they enter on their final
lineage specification (Ginhoux and Jung, 2014). It is likely that
because the epidermis is sealed around embryonic day 16 and
thus blocks entrance of circulating precursors at steady state,
epidermal LCs develop from embryonic macrophages that exist
in mice at this early stage and can reach the pre-epithelium
before it seals. The mucosal stratified epithelia, on the other
hand, are constantly nourished from the circulation, and thus
mucosal LCs can develop from circulating pre-DCs and mono-
cytes. This suggests that the epithelium holds the final develop-
mental cues for LC differentiation, and the precursors have the
plasticity to differentiate accordingly. Thus, we propose that
mucosal LCs represent genuine LCs. It should be pointed out
that adult murine BM cells can give rise to Langerhans-like cells
in vitro, as well as in vivo when they are administered into irradi-
ated Id2/ mice lacking LCs from embryonic precursors (Sere´
et al., 2013; Strobl et al., 1996). Moreover, human Langerhans-
like cells can differentiate in vitro from blood human BDCA-1+
DCs or CD1c+ DCs, which also contain Birbeck granules (Martı´-
nez-Cingolani et al., 2014; Milne et al., 2015). This indicates that
DCs have the potential to further differentiate into LCs, in line
with our in vivo results. Overall, this study proposes that murine
LCs can differentiate from at least three distinct precursors at
steady state: (1) embryonic fetal liver precursors, (2) pre-DCs,
and (3) monocytes.
Functionally, we have provided data from two distinct experi-
mental settings to show that mucosal and skin LCs have compa-
rable immunological functions. Moreover, we recently reported
that similar to skin LCs after cutaneous infection, oral LCsImmunity 43, 369–381, August 18, 2015 ª2015 Elsevier Inc. 377
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Figure 7. Skin and Mucosal LCs Have Similar Transcriptomic Signatures and Functions
Skin LCs, oral mucosal CD103+ andCD11b+ LCs, lung CD103+langerin+ DCs, and alveolarmacrophageswere sorted fromB6mice as described in Figure S6 and
subjected to global gene-expression analysis.
(A) K-means hierarchical clustering (K = 10) of 6,208 genes with expression values at the 75th percentile in the various cell subsets (results are an average of two to
four replicates from each cell subtype, and each replicate represents cells that were pooled from 15 mice).
(B) Bar graphs of individual gene expression in arbitrary units (a.u.). Error bars indicate mean values ± SEM.
(C) Principal-component analysis of the most variable transcripts expressed by the different antigen-presenting cell subsets.
(D) B6 wild-type or langerin-DTR mice injected with DT at day3 were sensitized on the abdomen or buccal mucosa with 1% TNCB and challenged 5 days later
with 0.5% TNCB on the right ear. Swelling was measured as the difference between the right and the unchallenged left ear. One representative experiment out of
three independent experiments is shown and presented as the mean values ± SEM (n = 5–8).
(E) B6 wild-type mice were immunized in the buccal mucosa with pACB-OVA, and 12 days later mucosal migratory DCs, CD11b+ LCs, CD103+ LCs, and LN-
resident DCs were sorted by FACS from the cervical LNs as described in Figure S6B. The various antigen-presenting cell subsets were incubated with purified
OT-I CD8+ T cells, and IFN-g amounts secreted to the supernatants were quantified by ELISA. Data were pooled from two independent experiments and
represent the mean ± SEM (n = 8–12).
See also Figure S6.
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regulate T cell immunity by inducing T regulatory cells after infec-
tion with an oral pathogen (Arizon et al., 2012; Kautz-Neu et al.,
2011). With regard to our observation that oral LCs failed to stim-
ulate CD8+ T cells, this is also in agreement with the known inca-
pability of skin LCs to activate these cells (Kaplan, 2010). Instead,
lamina propria DCs are the major cells presenting antigen to
CD8+ T cells and again resemble dermal DCs in mice immunized
intradermally with plasmid DNA, aswe previously reported (Elne-
kave et al., 2010). Such functional specialization between lamina
propria DCs and oral LCs further emphasizes the environmental
impact on cell differentiation given that both cells originate from
the same precursors. Environmental influences might also
explain the ability of macrophage-derived skin LCs to migrate
to the LNs upon stimulation, an activity that is considered to be
restricted to DCs (Tamoutounour et al., 2013). Indeed, we show
that although they originate from similar precursors, skin LCs
and alveolar macrophages varied greatly in their transcriptome
signature, and the latter were not shown to migrate to the LNs.
Besides oral LCs, vaginal epithelial DCs (VEDCs) have also
been reported to renew from BM precursors in steady state (Ii-
jima et al., 2007), whereas only a small fraction expresses lan-
gerin and are identified as LCs (Hervouet et al., 2010). The female
reproductive mucosa also undergoes cyclic changes, which af-
fects the epithelium and alters the relative frequencies of LCs
among VEDCs (Hervouet et al., 2010). It is possible that such
dissimilarity in the types and frequencies of antigen-presenting
cells in the oral and vaginal epithelia might reflect their separate
genesis, given that the oral epithelium originates from the ecto-
derm (like the epidermis), whereas both the endoderm and the
mesoderm create the vaginal epithelium (Kurita, 2010). Never-
theless, we have demonstrated here that similar to oral LCs,
about 25% of vaginal LCs originate from LysM progenitors and
can be segregated into CD103+ and CD11b+ subsets. Further-
more, in contrast to the dermis (Barrett et al., 1993; Bennett
et al., 2005), both oral and vaginal mucosa appear to have either
no or very few langerin+CD103+ DCs in the lamina propria (Her-
vouet et al., 2010), suggesting functional differences between
these tissues. Overall, whereas monocytes and pre-DCs are ex-
pected to give rise to vaginal LCs, their terminal differentiation,
as well as the LC:VEDC ratio, is shaped by intrinsic signals
of the vaginal epithelium. With regard to the cornea, a recent
study confirmed the presence of LCs in the epithelium; yet, these
LCs have been shown to have a unique CD11bloCD103lo pheno-
type (Hattori et al., 2011). Similar to vaginal mucosal cells, only a
small fraction of corneal epithelial antigen-presenting cells are
LCs, and we show here that about 30% of the latter originate
from LysM precursors. In addition, analogous to langerin-ex-
pressing cells in the skin, corneal LCs but not sub-mucosal
langerin+ DCs have been shown to be absent in langerin-DTA
mice (Hattori et al., 2011; Kaplan et al., 2005). This suggests
that corneal LCsmight arise from both embryonic and circulating
precursors, perhaps because of the unique status of the cornea
as an immune-privileged site, an issue that will require further
investigation.
In conclusion, our results demonstrate the presence of at least
two distinct populations of LCs in the mucosa. The CD103+ LCs
and part of CD11b+ LCs are derived from the CDP and pre-DC
differentiation pathways, whereas monocytes further contribute
to the CD11b+ LC population in steady state. In a broaderaspect, this study extends the current view of LC ontogeny to
three distinct LC precursor lineages acting in a tissue-specific
manner at steady state.
EXPERIMENTAL PROCEDURES
Ablation of Langerin-Expressing Cells In Vivo
Mice were treated once intraperitoneally with 1 mg DT (Sigma-Aldrich) in 150 ml
PBS. Control mice received PBS only, and no ablation of LCs was found in
these mice (data not shown).
Isolation and Identification of DCs and LCs
The gingival, buccal vaginal, corneal, or skin (ear) tissues were excised and
pooled from two to five mice per mucosal sample so that a sufficient numbers
of DCs and LCs were obtained for flow cytometry analysis, and these pooled
tissues were considered n = 1. In some experiments, epithelial sheets were
prepared by pre-digestion of tissue with 2 mg/ml Dispase II (Roche Diagnos-
tics) in PBS for 30–40 min (oral and skin tissues) or 60 min (vaginal mucosa)
at 37C. The epithelium and sub-epithelium (dermis or lamina propria) were
carefully separated with forceps and a binocular microscope. Mucosal tissues
were thenminced and treated with a collagenase type II (2 mg/ml; Worthington
Biochemicals) and DNase I (1 mg/ml; Roche) solution in PBS plus 2% fetal calf
serum (FCS) for 25 min at 37C in a shaker bath. A total of 20 ml of 0.5 M EDTA
per 2-ml sample was added to the digested tissues and incubated for an addi-
tional 10 min. Ear skin was excised, separated into two halves, and treated
similarly, except that 1mg/ml collagenasewas used. For DC isolation, the cells
were washed, filtered with a 70-mM filter, and stained extracellularly with anti-
bodies against CD45, MHCII, CD11c, CD103, CD11b, langerin (clone 4C7),
and EpCAM. In Figures 1A and 1D, 2A–2C, 3A, 5C, and 6, langerin staining
(clone 929F3.01) was performed by intracellular staining using Cytofix/Cyto-
perm solution (BD Biosciences) according to the instructions of the manufac-
turer. Of note, langerin expression by both surface and intracellular staining
approaches provided similar results, as demonstrated in Figure S1B. The
stained samples were run in LSR II (BD Biosciences) flow cytometers and
further analyzed by FlowJo software (Tree Star).
Immunofluorescence Staining
For whole-mount staining, the gingiva, buccal, and skin tissues were fixed in
ice-cold 95% ethanol for 40 min and subsequently digested in 1 M ammonium
acetate in water for 90 min at 37C or alternatively with 2 mg/ml Dispase II
(Roche Diagnostics) in PBS for 45 min at 37C. For staining frozen sections,
themaxilla was fixed overnight at 4C in 4%paraformaldehyde in PBS solution
and then washed for 1 week in 0.5 M EDTA in PBS that was changed every
other day. The tissue was cryopreserved in 30% sucrose (overnight at 4C),
embedded in optimal cutting temperature medium, and cryosectioned into
10-mm-thick sections. The cross sections, as well as the separated epithelium,
were washed three times in PBS, blocked in blocking buffer (5% FCS and
0.1% Triton X-100 in PBS) for 1 hr at room temperature, and incubated over-
night at 4C with the following primary antibodies: rat anti-CD207 (langerin)
clone eBioL31 (eBiosciences), goat anti-CD207 (langerin) clone E17 (Santa
Cruz Biotechnology), rat anti I-AI-E, clone M5/114.15.2 (BioLegend) or rabbit
anti-CD103, and clone H-260 (Santa Cruz Biotechnology). After three washing
steps in PBS, the samples were incubated with a secondary antibody (donkey
anti-goat IgG, donkey anti-rat IgG, or donkey anti-rabbit IgG; Jackson Immu-
noResearch) diluted 1:100 in blocking buffer for 1 hr at room temperature,
washed three times, stained with DAPI, and mounted. As a negative staining
control, primary antibody was omitted and replaced with blocking buffer. Sig-
nals were visualized and digital images were obtained with an Olympus BX51
fluorescence microscope.
BrdU Incorporation Assays
5- to 6-week-old mice were injected intraperitoneally with BrdU (2 mg/mouse;
Sigma) and subsequently received BrdU (0.8 mg/ml) in autoclaved drinking
water that was changed every other day. Tissues were prepared for flow cy-
tometry analysis as described in the previous section, and intracellular staining
for BrdUwas performedwith the BrdU Flow kit (BD) according to the manufac-
turer’s protocol.Immunity 43, 369–381, August 18, 2015 ª2015 Elsevier Inc. 379
Parabiosis
5- to 6-week-old female CD45.2+ and CD45.1+ B6 mice were matched for
body weight, housed in the same cage for 2 weeks, and then surgically
attached for 8 weeks. Blood exchange was confirmed 14 days after parabiosis
by examination of B cell chimerism via flow cytometry. Oral and skin tissues
were collected 8 weeks after the surgery for assessing the chimerism of
LCs. For each pair of joined mice, average chimerism was calculated as fol-
lows: (percent CD45.1+ cells in CD45.2+ mouse + percent CD45.2+ cells in
CD45.1+ mouse)/2.
Additional procedures can be found in the Supplemental Experimental
Procedures.
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